Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrates statistically significant and clinically meaningful improvement in progression-free survival compa...
Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales mile...
ObvioHealth, a global digital clinical trials company delivering stronger clinical evidence through tech-enabled trials, has launched an innovative e...
Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to ...
Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inh...
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the...
-- Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis – -...
Danuglipron demonstrated mean placebo-adjusted weight reductions ranging from -8% to -13% at 32 weeks and -5% to -9.5% at 26 weeks While most common adv...
This development underscores the company's commitment to advancing innovative solutions that provide relief and improved quality of life for the millions o...
Further develops its biosafety testing laboratories to meet local demand New labs complete 2nd phase of company’s € 29 million Biologics Test...
SBI-100 Ophthalmic Emulsion, a CB1 agonist/activator delivered as a topical eye drop, was developed to treat patients with elevated intraocular pressure ...
This site expansion will support faster enrolment in this cost-efficient, investigator-initiated study evaluating eftilagimod alpha (efti) in combination w...
The paper presents final analysis results from a multicenter, double-blind, phase 3, randomized controlled study (NCT05582629) evaluating the efficacy and ...
The RP2D of ivaltinostat (250 mg/m2) was determined by the Safety Review Committee (SRC) following a thorough safety data review from 3 cohorts of increasi...
© 2025 Biopharma Boardroom. All Rights Reserved.
